Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of antioxidant peptide DR8 in preparation of medicine for treating pulmonary fibrosis

A technology of pulmonary fibrosis and anti-oxidative peptides, applied in the field of biomedicine, can solve the problems of short half-life and large side effects of PFD

Inactive Publication Date: 2018-08-31
LANZHOU UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PFD has many side effects and a very short half-life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antioxidant peptide DR8 in preparation of medicine for treating pulmonary fibrosis
  • Application of antioxidant peptide DR8 in preparation of medicine for treating pulmonary fibrosis
  • Application of antioxidant peptide DR8 in preparation of medicine for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Embodiment 1, the preparation of DR8 intramuscular injection freeze-dried powder

[0067] Formula: DR8 (purity greater than 95%) 30.0g

[0068] Specific protein stabilizer, lyoprotectant / excipient 30.0g

[0069] Osmolality regulator (plasma 313 mOsm / kgH 2 O) 0.5-1L

[0070] pH regulator (pH 4-9) 0.5-1L

[0071] Pharmaceutical water Add to total volume 60L

[0072] The total mass of freeze-dried powder is 60.0-70.0g

[0073] Process: According to the conventional process for preparing freeze-dried powder, a total of 1,000 freeze-dried powders were prepared, each containing 60-70 mg of DR8 freeze-dried powder, and stored away from light.

[0074] The above-mentioned non-specific protein stabilizer and lyoprotectant are preferably mannitol, the excipient is preferably lactose, the osmotic pressure regulator is preferably NaCl, and the pH regulator is preferably citric acid / Tris-HCl buffer.

Embodiment 2

[0075] Embodiment 2, the preparation of DR8 oral preparation

[0076] Formula: DR8 (purity greater than 95%) 50.0g

[0077] Filler 85.0g

[0078] Adhesive 5.0g

[0079] Lubricant 10.0g

[0080] Total 200.0g

[0081] Process: According to the conventional process for preparing capsules, 1000 capsules are made, each capsule contains 50 mg of DR8 active ingredient, and the capsules are coated with an enteric-coated acrylic resin to make an enteric-coated preparation. Excipients such as fillers, adhesives, and lubricants are conventional excipients in pharmacy.

[0082] In addition, for oral preparations, the above-mentioned fillers, binders, lubricants and other auxiliary materials can be made into microspheres, microcapsules and nanospheres by polyester materials, and liposomes or nanospheres by chitosan. Granules, adding cholesterol, phospholipids and free fatty acids to prepare microemulsion preparations, etc. The preparation process of each dosage form is a conventional...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides novel medical application of an antioxidant peptide DR8 in preparation of a medicine for treating pulmonary fibrosis and belongs to the technical field of biological medicines.In-vitro pulmonary epithelial cell related experiments and in-vivo pulmonary fibrosis model mouse administration experiments show that the DR8 can achieve an effect of effectively inhibiting occurrence and development of pulmonary fibrosis and has a pulmonary fibrosis resistant effect and low cytotoxicity. Therefore, the DR8 can serve as an active ingredient, can be prepared into lyophilized powder, enteric coating preparations, microspheres, capsules, nanospheres, lipidosome, nanoparticles, microemulsion preparations and other various oral preparations capable of treating pulmonary fibrosis by adopting the conventional pharmaceutical process and excipients, and has excellent clinical application value.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, in particular to the application of a polypeptide DR8 with anti-oxidation effect in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is a respiratory disease characterized by diffuse and progressive pulmonary interstitial fibrous hyperplasia and pulmonary dysfunction caused by alveolar structural disorder. The occurrence of pulmonary fibrosis is associated with many diseases and is characterized by high morbidity and mortality and poor prognosis. The average survival time of patients after diagnosis is 2.5-3.5 years, and its incidence has been increasing year by year in recent years, which is extremely harmful to human health (J. Pneumologia. 2003, 29:1-5; Toxicol Appl Pharmacol. 2015, 286 :188-197). [0003] Since the pathogenesis of pulmonary fibrosis has not been clarified, there is a lack of effective treatments. At pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P11/00
CPCA61K38/08A61P11/00
Inventor 王锐谢俊秋张邦治蒋先兴闫志斌王丹
Owner LANZHOU UNIVERSITY